[{"id":"dc49e397-d619-4d29-a24b-f7ad79d40b19","acronym":"","url":"https://clinicaltrials.gov/study/NCT05264883","created_at":"2022-03-03T13:28:09.040Z","updated_at":"2024-07-02T16:35:46.935Z","phase":"Phase 3","brief_title":"Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML","source_id_and_acronym":"NCT05264883","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • aclarubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 06/28/2023","primary_completion_date":" 06/28/2023","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2023-05-29"},{"id":"0cbbac6c-e445-46d2-96c8-bd8a8d1f4c53","acronym":"","url":"https://clinicaltrials.gov/study/NCT03173612","created_at":"2021-01-18T15:38:53.387Z","updated_at":"2024-07-02T16:36:06.194Z","phase":"","brief_title":"The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia","source_id_and_acronym":"NCT03173612","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" GATA1","pipe":"","alterations":" ","tags":["GATA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • etoposide IV • idarubicin hydrochloride • mitoxantrone • aclarubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-08-03"},{"id":"df226a48-91d3-42e6-9f95-b3bd2cc6de70","acronym":"ALIVE","url":"https://clinicaltrials.gov/study/NCT04716114","created_at":"2021-03-26T11:56:14.334Z","updated_at":"2024-07-02T16:36:21.704Z","phase":"Phase 3","brief_title":"A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated","source_id_and_acronym":"NCT04716114 - ALIVE","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • fludarabine IV • Synribo (omacetaxine mepesuccinate) • aclarubicin • ruserontinib (SKLB-1028)"],"overall_status":"Recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 03/24/2021","start_date":" 03/24/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2021-11-02"}]